Tango Therapeutics (TNGX) Q3 2026 earnings review
Tango advances its pancreatic cancer drug, but operating costs double
Tango Therapeutics, a biotechnology company developing targeted cancer drugs, moved its lead pancreatic cancer treatment toward a final-stage trial while spending rose fast. In a mid-stage study pairing vopimetostat with a Revolution Medicines drug, tumors shrank in 82% of patients. Chief executive Malte Peters set a first-half 2027 start for a Phase 3 trial in untreated patients, backed by $978 million in cash and securities as quarterly operating costs nearly doubled to $78 million.
| 2L/3L pancreatic combo response rate | 82% 88% progression-free at 9 months |
|---|---|
| Cash and marketable securities | $977.5M down $36.5M from last quarter |
| Total operating expenses | $78.1M +97% from a year ago |
| 1L Phase 3 trial outlook | 1H 2027 start after FDA design discussions |
⚖️ Verdict: 🟢 Bullish
The story got better because the pancreatic cancer combination now has a clear regulatory design for a front-line Phase 3 trial and a potential shortcut to approval in second-line patients. Tango also cut early-stage research to focus its cash on PRMT5 drugs and test whether the combination works in a broader group of pancreatic tumors. Two cautions: management pushed its lung and brain cancer data from late 2026 to January 2027, and stock award changes for former executives more than tripled administrative expenses to $29 million.
The question now is whether Tango's drugs work on their own outside pancreatic cancer or depend on pairing with a partner's RAS blocker. If the standalone drugs shrink tumors in lung and brain cancer, the pipeline has multiple shots on goal; if not, the company relies on a combination where it does not own the second drug. January's clinical readouts for vopimetostat and TNG456 will decide.
🐂 Bull Case
Pancreatic Cancer Combination Moves Toward Late-Stage Trial
Tango's lead drug, vopimetostat, blocks PRMT5, an enzyme that cancer cells missing the MTAP gene need to survive. Chief executive Malte Peters said combining it with daraxonrasib, a Revolution Medicines drug targeting RAS mutations, could "raise the bar for patients with MTAP-deleted and RAS-mutant pancreatic cancer".
- Objective response rate (share of patients whose tumors shrank): 82% in second- and third-line patients, compared with 25% for vopimetostat alone in late 2025
- Nine-month progression-free survival (patients alive without cancer worsening): 88%, with median survival without worsening not yet reached
- Safety: generally well tolerated at the chosen daily dose of 200 mg vopimetostat plus 100 mg daraxonrasib
The results matter because they turn an early experiment into two paths to market. After meeting US regulators, the biotechnology group plans to start a Phase 3 trial in untreated patients in the first half of 2027. Peters also plans to discuss "the possibility of seeking accelerated approval of this combination in second line pancreatic cancer".
What to watch: the outcome of regulatory talks on second-line approval in 2027. An agreement to file on Phase 1/2 data would give Tango a commercial path years before the front-line Phase 3 trial finishes.
Almost $1 Billion in Cash Funds Late-Stage Plans
Late-stage cancer trials require large upfront commitments before a company earns product sales. Following equity raises earlier in the year, the Boston-based developer finished September with $977.5 million in cash and marketable securities, and no debt on its balance sheet.
By our math, total cash and marketable securities fell by $36.5 million from June's $1.01 billion balance, even as total operating expenses rose to $78.1 million. Interest income on the larger cash pile brought in $9.7 million, up from $1.8 million a year ago, which cushioned the quarterly loss.
What to watch: quarterly cash usage once the global Phase 3 trial begins in the first half of 2027. A moderate rise in cash usage would confirm Tango can fund the pivotal trial to readout without selling more shares.
New Erasca Trial and Broader Pancreatic Cancer Plans
Up to now, vopimetostat has targeted only tumors missing the MTAP gene, which make up about 35% of pancreatic cancers. Tango wants to widen both the drug partners it uses and the patients it can treat.
In November, the cancer drug maker began enrolling patients in a Phase 1/2 trial pairing vopimetostat with ERAS-0015, a RAS-blocking drug from Erasca, across pancreatic and lung cancers. It also plans a 25-patient trial in the first half of 2027 testing whether the combination works in pancreatic tumors that still have a normal MTAP gene.
What to watch: initial clinical results from the 25-patient normal-MTAP trial after it starts in 2027. Tumor shrinkage in those patients would open the remaining two-thirds of the pancreatic cancer population to vopimetostat.
🐻 Bear Case
Lung and Brain Cancer Readouts Slipped to January
Peters thanked his team for "the progress we have made in 2026 thus far" as the company prepares its next clinical updates. Beyond pancreatic cancer, the pipeline relies on vopimetostat alone in lung cancer and TNG456, a PRMT5 blocker built to cross into the brain for glioblastoma.
Three months ago, management planned to release initial clinical data for both the lung and brain cancer programs in the second half of 2026. The release pushed both disclosures to January 2027. Meanwhile, the pancreatic combination response rate settled at 82% at the August cutoff, down 10 percentage points from the 92% rate reported in the second quarter.
What to watch: the lung cancer and TNG456 data in January 2027. Weak response rates after the schedule slip would leave the company dependent on a single partner drug in pancreatic cancer.
Former Executive Pay Tripled Administrative Costs
As a clinical-stage biotechnology group without commercial products, Tango's spending should go mainly toward laboratory work and patient trials. Instead, overhead costs are taking a growing share of the budget.
General and administrative expenses — executive pay and corporate overhead — more than tripled from a year ago to $29.2 million, up from $8.9 million. By our math, overhead made up 37.4% of total operating expenses, up from 22.5% a year earlier. Management attributed the jump to staff costs and the "modification of previously issued equity awards for former executive officers".
What to watch: general and administrative spending in the fourth quarter. A drop back toward $15 million would show the former executive stock charges were a one-off rather than a permanent rise in overhead.
👓 Other Themes
Tango Drops Earlier Research to Focus on PRMT5
In October, the company announced "a strategic reprioritization of the Company’s research and development activities to focus on the advancement of PRMT5-targeted therapies". That shift lowered spending on earlier discovery programs, partially offsetting the 58.8% rise in research and development expenses to $48.9 million as vopimetostat and TNG456 advanced. Earlier candidates like TNG961, an HBS1L degrader listed in prior quarters, were absent from the release.
💲 Other KPIs
Share count rose 56.7% from 111.0 million a year ago and 16.0% from 149.9 million in the second quarter. The increase reflects equity offerings that built the $977.5 million cash balance, spreading the $68.4 million net loss across more shares to hold the per-share loss at $0.39.
Revenue remained at zero for a fourth straight quarter, compared with $53.8 million in the third quarter of 2025. The year-ago figure was an accounting bookend: Tango recognized all remaining upfront payments from Gilead Sciences after "the truncation of the collaboration agreement which concluded all research activities in August 2025".
Net other income — primarily interest earned on cash and marketable securities — more than doubled from $4.4 million last quarter and rose more than fivefold from $1.8 million a year ago. The increase followed the jump in marketable securities to $890.7 million and covered 12.4% of the quarter's operating expenses, by our math.
🔮 Guidance
Unchanged. Management said its $977.5 million in cash, cash equivalents and marketable securities will fund its current operating plan. By our math, the quarterly operating loss of $78.1 million less $9.7 million of other income equates to a $68.4 million net loss, giving the company more than three years of funding even as Phase 3 trial costs ramp up.
Advanced. Having completed FDA discussions on the trial design in the second half of 2026, the developer now plans to start the global randomized Phase 3 study in the first half of 2027. The trial will test 200 mg of vopimetostat plus 100 mg of daraxonrasib daily against standard chemotherapy, measuring both tumor response rate and progression-free survival.
Delayed. Management pushed the disclosure of Phase 1/2 vopimetostat monotherapy data in non-small cell lung cancer from the second half of 2026 to January 2027, when it will also share its broader lung cancer development strategy.
Delayed. The initial Phase 1/2 readout for the brain-penetrant PRMT5 inhibitor TNG456 moved from the second half of 2026 to January 2027, alongside the lung cancer update.
New. Tango plans to start a 25-patient Phase 1/2 combination study in the first half of 2027 testing vopimetostat with pan-RAS inhibitors in pancreatic cancer patients whose tumors still carry the MTAP gene.
❓ Key Questions
How will Tango secure Phase 3 daraxonrasib supply?
The Phase 3 pancreatic trial tests vopimetostat alongside Revolution Medicines' daraxonrasib, and the risk factors note reliance on securing clinical drug supply. Has Revolution Medicines committed commercial or Phase 3 supply, and who pays for the partner drug?
How many patients were in the 82% response rate?
The release reported an 82% response rate and 88% nine-month progression-free survival in evaluable patients treated at least 14 weeks before August 20, but omitted the exact patient count. How many patients were evaluated at the go-forward dose?
Why did Zoldonrasib drop out of the Phase 3 plan?
The October ESMO update included combinations with both daraxonrasib and zoldonrasib, yet the pivotal Phase 3 plan uses only daraxonrasib. How did the zoldonrasib cohort perform, and is that combination still active?
How much of the $29 million overhead was one-off?
General and administrative expenses rose by $20.3 million from a year ago partly because of stock award modifications for former executives. How much of third-quarter overhead was non-recurring stock compensation versus ongoing commercial hiring?